Parathyroid carcinoma (PC) is an extremely rare malignancy and therefore difficult to diagnose. PC cannot be confirmed before surgery because no specific biomarkers are available. PC underlies 1% of primary hyperparathyroidism (PHPT) cases and should be suspected in patients with biochemically severe disease, often kidney and bone manifestations \[[@bib1]\]. However, there are reports of increasing incidences in Australia, the United States, and Europe \[[@bib2]--[@bib4]\]. Reported recurrence rates are 20% to 50%, and 5-year survival in patients with metastatic disease is \<50% \[[@bib5]--[@bib7]\]. Radical primary surgery is the only curative treatment and is the first-line therapy also for recurrent disease.

The prognosis for inoperable disease is especially poor because no effective systemic therapies have been identified so far. There are some reports of treatment responses to external radiotherapy and anecdotal case reports of successful response to dacarbazine (an alkylating agent), sorafenib (a multikinase inhibitor), and immunotherapy with intradermal injections of synthetic human and bovine PTH peptide fragments \[[@bib8]--[@bib12]\]. Patients with metastatic PC usually die of severe hypercalcemia and renal insufficiency rather than of the tumor burden itself \[[@bib1]\].

We recently reported a case of recurrent, disseminated PC with complete remission in response to repeat surgery, temozolomide (TEM), external radiotherapy, cinacalcet, and bisphosphonates \[[@bib13]\]. This patient\'s PC demonstrated high O6-methylguanine DNA methyltransferase (*MGMT*) promoter methylation status. High *MGMT* promoter methylation is a known predictor of positive treatment response to TEM in other neuroendocrine tumors, such as aggressive pituitary tumors \[[@bib14]\] and pancreatic neuroendocrine tumors (NETs) \[[@bib15], [@bib16]\]. The MGMT enzyme is a DNA-repairing enzyme that counteracts the DNA-damaging effects of alkylating agents, such as TEM. Silencing of the *MGMT* gene by promoter methylation enhances the cytotoxic effects of TEM \[[@bib17]\]. *MGMT* promoter methylation status has not been systematically investigated in PC, except for the one previously reported case \[[@bib10]\].

Our aim here was to investigate whether high *MGMT* promoter methylation status is common in aggressive parathyroid tumors by studying an additional set of PCs (n = 11, including tumor tissue from the previously described patient with PC, patient 9) and one atypical parathyroid adenoma (this patient with APA is the daughter of the previously described patient 9) and corresponding patient characteristics and outcomes. We also describe treatment with TEM, external radiotherapy, cinacalcet, and denosumab in another patient with metastasized PC, who had an underlying *CDC73* mutation and low tumor *MGMT* promoter methylation status.

1. Materials and Methods {#s6}
========================

A. Patient Cohort {#s7}
-----------------

The study cohort consists of 12 patients with PC (n = 11) and 1 patient with atypical parathyroid adenoma (patient 12), all diagnosed, operated on, and treated at the Department of Endocrinology, Helsinki University Hospital between 1993 and 2018. The successful combined treatments of patient 9 (including TEM cycles for 1 year), resulting in complete remission, have been previously described \[[@bib13]\].

Patient data and laboratory results were obtained from the electronic patient record database at the Helsinki University Hospital in November 2018. Patient 11 was followed until the end of May 2019. All biochemical measurements were performed with in-house methods at HUSLAB, the central laboratory of our hospital. The most recent serum ionized calcium (normal range, 1.16 to 1.3 mmol/L at a pH of 7.4) and fasting plasma PTH (normal range, 15 to 70 ng/L) concentrations, as well as detailed information on therapies and recurrences, were retrieved from our electronic patient files. All histopathological characteristics of the tumors were reviewed by an expert parathyroid pathologist.

The Helsinki University Hospital Ethics Committee and the Finnish National Supervisory Authority for Welfare and Health (Valvira) (Dnro 8031/06.01.03.01/2015) approved the study. The patients have given their informed consent for participation in this study.

B. *MGMT* Promoter Methylation and *CDC73* Gene Mutation Status {#s8}
---------------------------------------------------------------

*MGMT* promoter methylation status was determined from formalin-fixed, paraffin-embedded (FFPE) tumor tissue excised at primary surgery (n = 10) or from a metastatic lesion (n = 2, patients 9 and 11). A mean methylation level \>20% of all investigated CpGs was considered methylated.

Tumor DNA for determination of *MGMT* promoter methylation status was isolated by using GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany), optimized for isolation of DNA from FFPE tissues. The quantity and quality of DNA were assessed by using NanoDrop 8000 Spectrophotometer (ThermoFisher Scientific, Waltham, MA). DNA concentrations were 300 to 1000 ng/μL per sample, and A260/A280 ratios in the range of 1.8 to 2.0 were considered satisfactory for purity standards. Unmethylated cytosine residues were converted to uracils by sodium bisulfite treatment of DNA (EpiTect Bisulfite Kit, Qiagen, Hilden, Tyskland), whereas methylated residues were left unchanged. Methylation of the five CpGs and one control CpG was analyzed in duplicated reactions by a cyclic minisequencing after PCR \[[@bib18]\]. One negative and two positive (high, low) controls were used in each run to confirm successful PCR and calculate cutoff values for automated genotype calling from 20 previous test runs.

*CDC73* mutation status was determined as previously described \[[@bib2]\]. None of the patients had multiple endocrine neoplasia type 1 based on genetic screening and/or the absence of multiple endocrine neoplasia type 1 manifestations on clinical follow-up. Next-generation sequencing of a PHPT gene panel (*AIRE, AIP, APC, CDC73, CDKN1A, CDKN1B, CDKN2B, CDKN2C, GCM2, GNA11, MEN1, PTH,* and *RET*) was introduced as a standard procedure in our clinic in 2016 and thus was performed among the patients diagnosed in 2016 and later (patients 1 and 2), with negative results.

2. Results {#s9}
==========

The clinical characteristics of the 12 patients are given in [Table 1](#tbl1){ref-type="table"}. Five are female and 7 are male, and the age at diagnosis ranged from 17 to 76 years. Four patients (patients 6, 8, 9, and 11) have been treated for local recurrent PC or distant metastases. All patients except patient 11 are in remission at the time of this report (serum ionized calcium \< 1.30 mmol/L). Patients 4 and 9 through 12 are characterized by familial PHPT. Patient 1 underwent neck exploration and parathyroidectomy because of tertiary hyperparathyroidism due to focal segmental glomerulosclerosis and end-stage renal failure. Histopathological diagnosis was parathyroid carcinoma of the right lower parathyroid, atypical adenoma of the right upper parathyroid, and hyperplasia of both left parathyroids. Patient 5 was diagnosed with gonadal dysgenesia (46XY/45X0) at birth. Patient 12 was diagnosed with severe PHPT during pregnancy and is the daughter of patient 9; her PHPT was due to an atypical parathyroid adenoma ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}).

###### 

Patient Characteristics

  Patient No.   Sex   Year of Primary Surgery   Age at Diagnosis (y)   Ionized Calcium at Diagnosis (mmol/L)   PTH at Diagnosis (ng/L)   Current Ionized Calcium (mmol/L)   Current PTH (ng/L)   Recurrent Disease
  ------------- ----- ------------------------- ---------------------- --------------------------------------- ------------------------- ---------------------------------- -------------------- -------------------------------------------------------------------------------------
  1             F     2016                      25                     1.35                                    2207                      1.23                               132                  No
  2             M     2018                      76                     2.11                                    2389                      1.21                               82                   No
  3             F     2014                      49                     2.08                                    576                       1.22                               75                   No
  4             M     2008                      17                     1.76                                    1187                      0.81                               16                   No
  5             M     2004                      35                     2.58                                    4000                      1.21                               93                   No
  6             M     2009                      45                     1.88                                    358                       1.18                               56                   Local recurrence 2012, reoperation + left lobectomy
  7             F     2010                      61                     2.71                                    3300                      1.21                               60                   No
  8             M     2007                      42                     1.5                                     178                       1.19                               97                   Recurrent PHPT in 2014, reoperation: left lower parathyroid: hyperplasia or adenoma
  9             F     2001                      48                     2.16                                    2020                      1.05                               31                   Previously published: recurrent, disseminated disease
  10            M     2011                      18                     1.88                                    693                       1.15                               108                  No
  11            M     1993                      32                     3.96 (total serum calcium)              1830                      1.62                               450                  Persistent, disseminated disease
  12            F     2008                      33                     1.96                                    823                       1.19                               91                   No

Abbreviations: F, female; M, male.

###### 

Details on Familial PHPT, CDC73 Germ-Line Mutations, Histopathological Tumor Characteristics, and *MGMT* Promoter Methylation Status

  Patient No.   Familial Disease       *CDC73* Germline Mutation      Location of Tumor                                                     Diagnosis                                                               Ki-67 (%)         Parafibromin Stain                *MGMT* Promoter Methylation
  ------------- ---------------------- ------------------------------ --------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------- --------------------------------- -----------------------------
  1             No                     No                             Right lower parathyroid; right upper parathyroid; left parathyroids   Atypical adenoma; carcinoma (vascular invasion); hyperplasia            APA: 10, PC: 15   Unreliable, with negative spots   Low
  2             No                     No                             Right lower parathyroid                                               Carcinoma (vascular invasion)                                           3                 Negative                          Low
  3             No                     No                             Right lower parathyroid                                               Carcinoma (vascular invasion)                                           10                Negative                          Low
  4             Aunt                   No                             Left and right lower parathyroids; right upper parathyroid            Carcinoma (vascular and capsular invasion); hyperplasia or metastasis   5                 Positive                          Low
  5             No                     No                             Right lower parathyroid                                               Carcinoma (invasion of vasculature and surrounding tissue               10                Positive                          Low
  6             No                     No                             Left upper parathyroid                                                Carcinoma (vascular invasion)                                           10                Negative                          Low
  7             No                     No                             Left upper and right lower parathyroids                               Both carcinoma (invasion in surrounding fat tissue)                     20                Positive                          Low
  8             Yes                    No                             Left upper parathyroid; right upper parathyroid                       Carcinoma (capsular and vascular invasion); hyperplasia                 5                 Positive                          Low
  9             Daughter and brother   No                             Primary tumor not available                                           Metastasis                                                              10                Negative                          High, 35%
  10            Several                Gross deletion (exons 1--10)   Right upper parathyroid; left upper parathyroid                       Carcinoma (vascular invasion); atypical adenoma                         8                 Negative                          Low
  11            Several                Gross deletion (exons 1--10)   Primary tumor not available                                           Metastasis                                                              20                Negative                          Low
  12            Mother and uncle       No                             Left Lower left parathyroid                                           Atypical parathyroid adenoma                                            5                 Focal positive spots              Low

Abbreviation: APA, atypical parathyroid adenoma.

Data on familial PHPT, *CDC73* gene mutation status, affected parathyroid glands, histopathological criteria of PC, and Ki67 and parafibromin staining are given in [Table 2](#tbl2){ref-type="table"}. All tumors except that from patient 9 (the previously published case \[[@bib13]\]) had low tumor *MGMT* promoter methylation status.

A*.* Surgery, TEM, and Other Adjuvant Treatments in a Patient With a CDC73 Mutation, Disseminated PC, and Low MGMT Methylation Status {#s10}
-------------------------------------------------------------------------------------------------------------------------------------

Patient 11 was diagnosed with severe PHPT due to PC in 1993 at age 32 years. He carries a *CDC73* gross deletion of exons 1 to 10, as previously reported \[[@bib18]\]. Parafibromin staining was negative and Ki67 was 20% ([Table 2](#tbl2){ref-type="table"}). He was not cured by primary surgery and has been operated on several times because of metastases in the neck and in the vicinity of the thoracic spine. At the end of 2017, his serum ionized calcium (1.45 to 1.69 mmol/L) and PTH (786 ng/L) concentrations again increased. The underlying lesion was difficult to localize, and the patient underwent planar scintigraphy with ^123^I 99mTC-sestamibi, 18F-fluorodeoxyglucose positron emission tomography and 11C-methionine positron emission tomography/MRI. MRI confirmed a recurrent metastasis in vertebra C6 ([Fig. 1A](#fig1){ref-type="fig"}) and a 3-cm tumor in the right kidney ([Fig. 1B](#fig1){ref-type="fig"}) that proved to be papillary type 1 renal carcinoma. *MGMT* methylation status, determined from the metastatic lesion resected in March 2018, was low ([Table 2)](#tbl2){ref-type="table"}.

![(A) 1.5-T axial plane T2-weighted MRI demonstrating a metastatic soft tissue mass in the left anterolateral cortex of C6 (straight arrow). (B) Contrast-enhanced CT scan in coronal plane of the right kidney shows multiple cortical cysts and a solid tumor mass (arrowheads). (C) Contrast-enhanced CT scan in axial plane reveals marked growth of the C6 metastatic mass, which has caused a large lytic cortical lesion (curved arrow).](js.2019-00175f1){#fig1}

The patient was treated with TEM cycles (280 mg for 5 days, with 28-day intervals) between March and October 2018, cinacalcet, zoledronic acid 4 mg every 4 weeks, and external radiotherapy of the C6 metastatic lesion.

In October 2018, CT demonstrated growth of the C6 metastasis ([Fig. 1C](#fig1){ref-type="fig"}) and lung metastases. TEM treatment was subsequently stopped. Zoledronic acid was replaced by denosumab 120 mg every 4 weeks, and cinacalcet was discontinued in March 2019 because of nausea. In January 2019, thoracic CT demonstrated stable disease, with minor tumor shrinkage. As of May 2019, the serum ionized calcium was 1.62 mmol/L and creatinine level was 117 µmol/L. This patient is also the uncle of patient 10, who was diagnosed with severe PC at age 18 years and carries the same *CDC73* gross deletion \[[@bib18]\]. This patient had two abnormal parathyroids and low *MGMT* promoter methylation of the PC ([Table 2](#tbl2){ref-type="table"}).

3. Discussion {#s11}
=============

We studied *MGMT* promoter methylation status in aggressive parathyroid tumors from 12 (11 with PC and 1 with atypical parathyroid adenoma) well-characterized patients operated on for PHPT; this has not previously been done in any series of PC/aggressive parathyroid tumors before. High *MGMT* methylation status was found in only one of these tumors (patient 9), as previously described \[[@bib10]\]. High *MGMT* promoter methylation is a known predictor of positive treatment response to TEM in other NETs, such as aggressive pituitary tumors and pancreatic NETs \[[@bib14]--[@bib16]\].

All parathyroid tumors underwent careful histopathological examination by our expert parathyroid pathologist. In addition, all patients are under regular follow-up and have been treated accordingly for possible recurrent PHPT in our institution. In patient 1, PC may have been driven by proliferation of parathyroid cells due to tertiary hyperparathyroidism and underlying end-stage renal failure, as describe by Miki et al \[[@bib19]\]. We wanted to include both familial and sporadic cases of PC to explore whether these factors could be related to *MGMT* promoter methylation status. Some of the familial cases may represent phenocopies. For patient 9, who had PC and high *MGMT* methylation status, and her daughter (patient 12), the underlying gene defect has not been identified. For instance, possible *GCM2* mutations have not been ruled out. *MGMT* methylation was also low in the atypical adenoma of the daughter, revealing distinct methylation reprogramming of *MGMT* promoter in the tumor of this first-degree relative. According to the current study, the *MGMT* gene promoter is thus supposedly not regularly methylated in aggressive parathyroid tumors. However, because PC is very rare, only 12 patients/tumors were included in the present series. It is difficult to gather a large enough PC cohort for more comprehensive analyses. Considering the prevalence of PC, our patient cohort is of reasonable size.

There are different methods of assessing *MGMT* methylation status. Although immunohistochemistry is the simplest and cheapest method, it does not correlate well with other methods or with clinical treatment response to alkylating agents \[[@bib20]\]. Bisulfite treatment methylation-specific PCR, as used in our study, is considered the gold standard because it gives quantitative information on *MGMT* methylation status \[[@bib21]\]. It is, however, possibly associated with inaccurate results because only a few CpG methylation sites are analyzed. In addition, promoter methylation status of tumors with variable methylation status of specific CpG sites might be falsely considered low \[[@bib20]\]. With the cycling minisequencing method used, false results have been minimized by using duplicate reactions, controls, and follow-up of results from previous runs. Because different PCR assays can yield different results, the specificity and sensitivity depend on the method used. For the current study it depends on the PCR protocol \[[@bib22]\].

Methylation-specific PCR, with its high sensitivity, is widely used for assessing *MGMT* methylation in the research setting but suffers from increased false-positivity. Pyrosequencing is considered the most accurate and robust method for determining *MGMT* methylation status \[[@bib23], [@bib24]\]. With FFPE DNA, there is a risk of false-positive or false-negative results, especially when the DNA quality and/or quantity is low \[[@bib25]\]. We tried to avoid inaccurate results by isolating DNA with a method designed for FFPE material and used only specimens with good DNA concentrations and satisfactory purity (260/280 1.8 to 2.0).

The *MGMT* gene is epigenetically inactivated by promoter hypermethylation in ∼40% of primary glioblastomas \[[@bib26]\], in which *MGMT* methylation is associated with improved overall survival \[[@bib27]\]. Owen *et al.* \[[@bib28]\] studied MGMT expression in gastroenteropancreatic NETs as well as in NETs originating from the lung and thymus. At 2 years, patients with low MGMT protein expression on immunohistochemistry receiving capecitabine and TEM treatment had better outcomes than patients with higher MGMT protein expression. However, there were also patients in the high MGMT expression group who responded to treatment (*i.e.,* reached partial remission or stable disease) \[[@bib28]\]. Some studies did not show different treatment response to TEM according to *MGMT* status \[[@bib29]\]. It is thus possible, as in patient 11 of the current study, that partial response or stable disease can be achieved with TEM in some patients with PC regardless of *MGMT* status, as previously demonstrated in other NETs. However, further studies are needed to clarify this.

Because PC is very rare, treatment of patients with recurrent PC could benefit from developments in personalized cancer care in the future. Some suggested treatment targets include different inhibitors of the PIK3CA-PTEN-mTOR-AKT pathway, such as sorafenib and everolimus \[[@bib12], [@bib30], [@bib31]\]. For patients with recurrent PC, efficient treatment therapies are scarce and thus urgently needed. Demonstration of high *MGMT* methylation status could thus serve as a predictor of positive treatment response to TEM and tailoring of the treatment.

4. Conclusion {#s12}
=============

We recommend *MGMT* promoter methylation testing in recurrent PC not curable by surgery because high methylation status could indicate good treatment response to TEM. Some treatment response may be achieved regardless of *MGMT* methylation status.
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